ASCO GI 2016: FOLFOX + ziv-aflibercept placebo adding anti-angiogenic agent to chemotherapy in advanced gastric and GE junction adenocarcinoma
Joel Randolph Hecht, MD of UCLA Health discusses ASCO GI 2016: FOLFOX + ziv-aflibercept placebo adding anti-angiogenic agent to chemotherapy in advanced gastric and GE junction adenocarcinoma at ASCO ...
Author: ASCOGI2016
Added: 01/22/2016
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Adenocarcinoma | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | Health